Investors Buy Large Volume of Ocugen Call Options (NASDAQ:OCGN)

Key Points

• Unusual options activity drove a sharp move: investors bought 5,566 call options (about +62% vs. average) as OCGN rallied 25.9% to $2.23 on ~26.15M shares versus a ~6.15M average volume.
• Positive catalysts likely spurring the buying include Oppenheimer initiating coverage at Outperform with a $10 target, HC Wainwright raising near‑term estimates, and Ocugen completing Phase‑3 enrollment for its OCU400 gene‑therapy program.
• Several institutions materially increased stakes (e.g., UBS +373%, Goldman +2,256%, State Street +194%), but Ocugen remains unprofitable with negative EPS and margins, so upside is paired with significant clinical and financial risk.

Ocugen, Inc. (NASDAQ:OCGN - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors acquired 5,566 call options on the company. This is an increase of 62% compared to the typical volume of 3,429 call options.

Ocugen Stock Up 25.9%

OCGN traded up $0.46 on Wednesday, hitting $2.23. 26,153,581 shares of the company were exchanged, compared to its average volume of 6,150,142. The company has a market cap of $730.89 million, a PE ratio of -9.62 and a beta of 2.75. Ocugen has a 12 month low of $0.52 and a 12 month high of $2.32. The company has a debt-to-equity ratio of 8.04, a quick ratio of 1.06 and a current ratio of 1.06. The stock's fifty day moving average is $1.59 and its 200-day moving average is $1.44.

Ocugen (NASDAQ:OCGN - Get Free Report) last issued its earnings results on Wednesday, March 4th. The company reported ($0.06) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.06). The business had revenue of ($0.19) million during the quarter, compared to the consensus estimate of $0.86 million. Ocugen had a negative return on equity of 2,626.38% and a negative net margin of 1,192.18%. Equities research analysts predict that Ocugen will post -0.2 EPS for the current fiscal year.

More Ocugen News

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Oppenheimer initiated coverage at Outperform with a $10 price target, highlighting Ocugen’s gene‑therapy pipeline for blinding ocular disorders — a high‑profile analyst start that likely drove buying interest. Oppenheimer Starts Ocugen at Outperform
• Positive Sentiment: HC Wainwright raised several near‑term (Q1–Q4 2026) EPS forecasts and lifted FY2026 estimates, signaling slightly improved near‑term profitability expectations; the shop also published a long‑term FY2030 estimate that implies material upside if clinical success continues. HC Wainwright Coverage Summary
• Positive Sentiment: Ocugen announced completion of enrollment for the Phase 3 trial of OCU400, a clear operational milestone that de‑risks the program’s timeline and supports upcoming catalysts. Phase 3 Enrollment Complete
• Positive Sentiment: Unusually large options activity: traders bought ~5,566 call contracts (roughly +62% vs. avg call volume). Heavy call buying often signals bullish positioning or speculative interest ahead of catalysts.
• Positive Sentiment: Company press coverage summarized 2025 results and clinical progress across the gene‑therapy pipeline, reinforcing the narrative of clinical advancement. 2025 Results & Clinical Progress
• Neutral Sentiment: Article comparing Ocugen to peers (ArriVent) provides sector context but no direct catalyst. Sector Comparison
• Negative Sentiment: HC Wainwright trimmed several longer‑range FY2027–FY2029 EPS estimates (and materially reduced FY2029 from prior expectations), signaling caution about multi‑year revenue ramps and pushing out some upside. HC Wainwright Longer‑Term Revisions
• Negative Sentiment: Seeking Alpha published a downgrade after OCU410 data release, a reminder that clinical readouts can trigger swift negative re‑rating if results disappoint. OCU410 Downgrade

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS Group AG increased its stake in Ocugen by 373.2% in the fourth quarter. UBS Group AG now owns 4,849,353 shares of the company's stock worth $6,547,000 after purchasing an additional 3,824,474 shares during the period. State Street Corp increased its position in shares of Ocugen by 193.6% during the fourth quarter. State Street Corp now owns 3,978,738 shares of the company's stock worth $5,371,000 after acquiring an additional 2,623,361 shares during the period. Marshall Wace LLP bought a new stake in shares of Ocugen during the fourth quarter valued at approximately $3,417,000. Goldman Sachs Group Inc. boosted its holdings in shares of Ocugen by 2,256.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,302,475 shares of the company's stock valued at $3,108,000 after purchasing an additional 2,204,765 shares during the period. Finally, Renaissance Technologies LLC grew its stake in Ocugen by 485.9% in the fourth quarter. Renaissance Technologies LLC now owns 1,700,400 shares of the company's stock worth $2,296,000 after purchasing an additional 1,410,200 shares in the last quarter. 10.27% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on OCGN shares. Chardan Capital restated a "buy" rating and set a $7.00 target price on shares of Ocugen in a research note on Thursday, March 5th. Oppenheimer began coverage on shares of Ocugen in a research report on Wednesday. They issued an "outperform" rating and a $10.00 target price for the company. Wall Street Zen downgraded shares of Ocugen from a "hold" rating to a "sell" rating in a research report on Saturday. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Ocugen in a report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.00.

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.